J.W. Cole Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

J.W. Cole Advisors’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7,681	Closed	-$213K	–	1465
2025 Q3	$213K	Buy	+7,681	New	+$194K	﹤0.01%	1406
2023 Q3	–	Sell	-6,250	Closed	-$213K	–	738
2023 Q2	$213K	Sell	6,250 -1,156	-16%	-$36.3K	0.02%	686
2023 Q1	$223K	Buy	7,406 +146	+2%	+$4.52K	0.02%	694
2022 Q4	$205K	Sell	7,260 -1,811	-20%	-$57.5K	0.02%	685
2022 Q3	$298K	Buy	9,071 +158	+2%	+$5.8K	0.02%	535
2022 Q2	$281K	Sell	8,913 -4,731	-35%	-$165K	0.02%	573
2022 Q1	$627K	Sell	13,644 -2,111	-13%	-$101K	0.04%	388
2021 Q4	$965K	Buy	+15,755	New	+$1.09M	0.06%	311
2021 Q3	–	Sell	-18,384	Closed	-$1.7M	–	490
2021 Q2	$1.7M	Sell	18,384 -72	-0.4%	-$6.12K	0.13%	179
2021 Q1	$1.64M	Sell	18,456 -8,228	-31%	-$816K	0.16%	160
2020 Q4	$2.49M	Buy	26,684 +21,291	+395%	+$1.7M	0.26%	93
2020 Q3	$344K	Sell	5,393 -5,750	-52%	-$337K	0.03%	498
2020 Q2	$581K	Buy	+11,143	New	+$478K	0.09%	209
2020 Q1	–	Sell	-12,869	Closed	-$431K	–	126
2019 Q4	$431K	Buy	+12,869	New	+$409K	0.05%	330

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

J.W. Cole Advisors's ARKG Position: Q4 2025 in Review

J.W. Cole Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q4 2025, closing a stake of 7,681 shares — an estimated $213K sold.

J.W. Cole Advisors first reported a position in ARKG in Q4 2019 and held it in 14 quarters. The position peaked at $2.49M in Q4 2020. 238 funds tracked by Wall St. Rank hold ARKG as of Q4 2025.

J.W. Cole Advisors reported no remaining ARK Genomic Revolution ETF position as of Q4 2025 after selling out during the quarter.
J.W. Cole Advisors sold 7,681 ARK Genomic Revolution ETF shares in Q4 2025, an estimated $213K.
J.W. Cole Advisors first reported a position in ARK Genomic Revolution ETF in Q4 2019 and held it in 14 quarters.
J.W. Cole Advisors's ARK Genomic Revolution ETF position peaked at $2.49M in Q4 2020.
238 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q4 2025.

Based on J.W. Cole Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.